Techcyte and Evident add flexible scanner purchasing models for digital pathology

Techcyte and Evident said Oct. 17 that labs can now buy Pramana whole-slide scanners outright or use pay-per-slide and pay-per-period options bundled with Techcyte Fusion. The move is aimed at making end-to-end digital pathology easier to adopt and scale across multiple lab workflows in the U.S. and Europe.

Why it matters: - Labs can now choose a capital purchase or usage-based model for Pramana scanners and Techcyte Fusion. - The new options are designed to reduce upfront barriers and tie costs more closely to scanner use. - The partnership expands access to end-to-end digital pathology across multiple workflows, not just histology.

What happened: - Techcyte and Evident announced new acquisition options for Evident’s Pramana autonomous whole-slide imaging scanners paired with Techcyte Fusion. - The announcement came Oct. 17, 2026, alongside Pathology Visions 2026 in San Diego. - Laboratories that prefer ownership can buy the scanners outright. - Laboratories that want variable costs can choose pay-per-slide or pay-per-period pricing. - The bundled offer combines scanners and Fusion in one package.

The details: - Techcyte develops Fusion, an enterprise digital pathology platform. - Evident develops the Pramana line of autonomous whole-slide imaging scanners. - The companies said they have worked together for several years. - The joint workflow covers autonomous imaging, case handling and reporting. - The collaboration spans histology, cytology, hematology, microbiology and parasitology. - Techcyte said the partnership is built to make digital pathology simpler for labs, from the scanner to the final report. - Evident said the Pramana scanners’ modular architecture and quality-assured imaging support scaling capacity on demand. - Evident also said the new models can help remove hidden operational costs. - Techcyte Fusion and Evident’s Pramana scanners are for Research Use Only in the United States. - Pramana is a trademark of Evident Corporation or its subsidiaries. - Techcyte will be at booth #410 at Pathology Visions 2026. - Evident will be at booth #106 at Pathology Visions 2026.

Between the lines: - The companies are pushing beyond a standard hardware-and-software bundle and into more flexible commercial terms. - Usage-based pricing may appeal to labs that want to add capacity without committing to a full equipment purchase. - The partnership also signals a broader push to make digital pathology more modular across different lab specialties.

What's next: - Labs can learn more about purchasing and operational options at Techcyte.com or EvidentScientific.com. - The companies will showcase the products at Pathology Visions 2026 in San Diego, Oct. 16-18. - Techcyte and Evident are likely to use the event to push adoption of the new acquisition models.

The bottom line: - Techcyte and Evident are trying to make digital pathology easier to adopt by pairing their platform and scanners with more flexible payment choices.